Overview
I am a clinically-oriented diagnostic physician with clinical expertise in the pathologic diagnosis of hematologic cancers including tumors of the bone marrow, lymphoid tissue, spleen and pre-malignant hematologic conditions. Another area of interest is blood cancer classification with molecular and genetic profiling. In the research program, we focus on molecular mechanisms of tumor progression, cell-of-origin, biomarkers, and novel therapeutic strategies in lymphoma, myeloma and leukemia. In addition to patient care and translational research, medical education and communication are also part of focus. I provide persistent support for the physician-scientist program and Blood Cancer Pathology program in the department and cancer center. Many residents, fellows, graduates and postdocs have worked and been trained in our program. We perform comprehensive clinical and research functions that include bone marrow, lymphoma pathology, clinical flow cytometry, cytogenetics, molecular diagnostics and outside services.
I am currently the director of hematopathology division and Vice Chair of Research in the Department that provides diagnostic consultation services and relevant specialized testing for patients with various types of acute and chronic leukemia, lymphoma and benign hematologic disorders. I am specialized in the diagnosis of hematological disorders, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, B and T-cell lymphomas, Hodgkin lymphoma, cutaneous and orbital lymphomas and benign bone marrow and lymph node disorders.
Our clinical and research collaborative groups have been supported by various funding resources since 2006 and have published more than 300 original peer-reviewed articles and review articles, many in high- impact journals (Nature Clin Onc Rev, JCO, JAMA, Lancet, Blood, JHO, Leukemia and Clinical Cancer Research). The contributions to the hematology field include the development of novel diagnostic algorithms, molecular and genetic biomarkers for classification of blood cancer, lymphoid neoplasms and lymphoid diseases.
Office Hours
Division of Hematopathology and Department of Pathology, Duke University School of Medicine, Duke University Medical Center and Cancer Institute, 40 Duke Medicine Circle, Room 265M, Box 3712, Duke South, Green Zone, Durham, NC 27710. Office Phone: 1-919-668-7568
Current Appointments & Affiliations
Recent Publications
Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology.
Journal Article Cell Rep Med · March 13, 2025 Diffuse large B cell lymphoma (DLBCL) is a heterogeneous B cell neoplasm with variable clinical outcomes influenced by both tumor-derived and lymphoma microenvironment (LME) alterations. A recent transcriptomic study identifies four DLBCL subtypes based on ... Full text Link to item CiteLasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.
Journal Article Blood · March 6, 2025 Myeloid differentiation primary response protein 88 (MYD88) is a key adaptor molecule in the signaling pathways of toll-like receptor and interleukin-1 receptor. A somatic mutation resulting in a leucine-to-proline change at position 265 of the MYD88 prote ... Full text Link to item CitePrognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.
Journal Article Res Sq · January 6, 2025 Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare and aggressive lymphoma with molecular heterogeneity not well characterize. In this study, we performed next-generation sequencing analysis for a large number of DNA and RNA samples from ... Full text Link to item CiteRecent Grants
Cancer Prevention-Interception against MGUS Progression (Admin Core)
ResearchPrincipal Investigator · Awarded by Baylor College of Medicine · 2023 - 2027Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026Role of SLAMF7 in Racial Disparities in Myeloma
ResearchCo Investigator · Awarded by National Cancer Institute · 2023 - 2026View All Grants